PharmExec Blog
Follow Us
RSS
Bookstore
Author Archives: Oriana Schwindt
TB Alliance Trumpets New, Improved Drugs at World Health Assembly
Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts [...]
A Crash Course in SaaS
Image via Wikipedia
Our magazine is called Pharmaceutical Executive—indicating a focus on the c-suite. But we know many of our readers aren’t executives (yet), and may not have quite the same in-depth knowledge as their bosses. So, for those who hear the term “SaaS” bandied about in conversations and fake their way through discussions about it [...]
Lower Lilly Earnings the Shape of Things to Come
Eli Lilly announced its first quarter financial results on April 19. But even though the company trumpeted a global revenue growth rate of 9 percent—$5.49 billion, compared to Q1 2009’s $5.05 billion—net income fell 5 percent to $1.25 billion.
Part of the blame for that 4 percent difference, the company said, lies with the passage of [...]
Posted in Strategy Tagged Earnings, Effexor, Eli Lilly, John Lechleiter, Lipitor, pricing, Seroquel Leave a comment
Avandia Trial in Trouble
GSK’s Avandia just won’t stay out of the news. Now comes a report from The Wall Street Journal that the FDA is considering dealing the beleaguered diabetes drug another blow by stopping one of its safety trials.
The TIDE trial, which received approval in 2007, pits Avandia (rosiglitazone) against Takeda’s Actos (pioglitazone), a drug that [...]
Posted in Strategy Tagged Actos, Avandia, FDA, Geodon, GSK, Pfizer, Takeda, US Senate Finance Committee Leave a comment
Astellas and OSI Come Together